A new oral GLP-1 receptor agonist, orforglipron, is revolutionizing weight management by offering a needle-free alternative to injectables. Clinical trials show significant weight loss and metabolic improvements, mirroring injectable efficacy. This convenient daily tablet promises better adherence and broader accessibility for individuals seeking effective obesity care, marking a significant shift in treatment delivery.from LifeStyle - Latest Lifestyle News, Hot Trends, Celebrity Styles & Events https://ift.tt/iyVS3xE
